Clinical trial Recruiting at 1 site Observational Ages 18 to 65

Evaluating brain function and psychological effects of cell therapy in autoimmune hemolytic anemia

Official title: Brain Function and Psychological Assessment in Patients With Autoimmune Hemolytic Anemia Undergoing Cell Therapy

Run by Institute of Hematology & Blood Diseases Hospital, China · NCT06921980 · Data updated 2026-11-12

This study is testing how CAR T-cell therapy affects thinking and mental health in people with autoimmune hemolytic anemia to help improve their treatment and quality of life.

Quick facts

Study typeObservational
Ages18 Years to 65 Years
SexAll
Enrollment20 (estimated)
SponsorInstitute of Hematology & Blood Diseases Hospital, China
Academic / other
Drugs / interventionsCAR T
Locations1 site (Tianjin, Tianjin Municipality)
StatusRecruiting
StartedFebruary 25, 2025
Main results expectedDecember 31, 2027
Study endsDecember 31, 2028
Registry record updatedNovember 4, 2026
Trial IDNCT06921980 on ClinicalTrials.gov

Is this trial a fit for you?

Likely a good fit

Ideal candidates include adults aged 18-65 with a diagnosis of autoimmune hemolytic anemia who are set to receive cell therapy.

Probably not a fit

Patients with a history of psychiatric illness or severe brain disease may not benefit from this study.

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This observational study investigates the cognitive and psychological impacts of cell therapy, specifically CAR T-cell therapy, on patients diagnosed with autoimmune hemolytic anemia (AIHA). It aims to assess brain function and psychological well-being to identify potential impairments early, allowing for timely interventions. By understanding these effects, the study seeks to enhance treatment strategies and improve the overall quality of life for patients undergoing this innovative therapy.

Why it matters

Potential benefit: If successful, this study could lead to safer and more effective treatment strategies for patients with autoimmune hemolytic anemia.

How similar studies have gone: While cell therapy has shown promise in treating hematologic and autoimmune diseases, the specific focus on cognitive and psychological impacts in this context is relatively novel.

Who can join: the full rules

Show full inclusion / exclusion criteria
Inclusion Criteria:

* Diagnosis of AIHA
* Subjects will receive cell therapy such as CAR T-cell therapy
* Male or female, aged 18-65 years
* Willing and able to comply with the requirements for this study and written informed consent

Exclusion Criteria:

* History of psychiatric illness
* History of severe brain disease
* Subjects that the investigator believes have other reasons that make them unsuitable for inclusion in this study

Where it's running

  • Regenerative Medicine Center
    Tianjin, Tianjin Municipality, China
    Recruiting

Study contacts

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

How to take part

  1. Review the eligibility criteria above with your treating physician.
  2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
  3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.
Last reviewed 2026-11-14 by the Find a Trial editorial team. Information on this page is for educational purposes and is not medical advice. Always consult qualified healthcare professionals about clinical trial participation.